RecruitingNot ApplicableNCT06697600

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Sponsor

University of Rochester

Enrollment

1,020 participants

Start Date

Jul 11, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Oncology Myeloid Leukemia, Acute

Summary

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a decision-support program to help older adults newly diagnosed with acute myeloid leukemia (AML) and their caregivers make informed treatment decisions — including whether to pursue aggressive treatment or focus on comfort care. **You may be eligible if...** - You are 60 years or older - You have been newly diagnosed with AML (including myeloid sarcoma or AML with central nervous system involvement) - You have not yet started cancer-directed treatment (temporary measures to lower white blood cell counts are acceptable) **You may NOT be eligible if...** - You have already started cancer treatment - You are unable to communicate with the study team - You have cognitive difficulties that would prevent meaningful participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALUR-GOAL

Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.